Key Takeaways
- Lupin’s wholly‑owned subsidiary VISUfarma has secured an exclusive license to develop, register, commercialize, market, promote, distribute and sell YUVEZZI™ (carbachol & brimonidine tartrate ophthalmic solution 2.75%/0.1%) in the European Union, United Kingdom, Switzerland, Norway and Iceland.
- Under the agreement VISUfarma will make a strategic investment in Visus Therapeutics and is eligible to receive regulatory and commercial milestone payments as well as tiered royalties based on net sales.
- YUVEZZI™ is the first and only once‑daily, dual‑agent eye drop approved by the U.S. FDA for the treatment of presbyopia, offering a novel mechanism that constricts the pupil with carbachol while preventing excessive dilation with brimonidine.
- Lupin views the partnership as a cornerstone of its Specialty Care strategy, expanding its ophthalmology portfolio and strengthening its presence in key European markets.
- Tenpoint Therapeutics will continue to advance YUVEZZI™’s regulatory filings worldwide, having already submitted an MMA in the UK via the MHRA’s International Recognition Procedure and pursuing approvals in additional regions.
- Safety data indicate the most common adverse events are headache, impaired vision and temporary eye pain or irritation, which are generally mild and transient.
Overview of the Licensing Agreement
On August 20, 2026, Lupin Limited announced that its wholly‑owned subsidiary VISUfarma B.V. had entered into an exclusive licensing agreement with Visus Therapeutics Inc., a U.S.–based wholly‑owned subsidiary of Tenpoint Therapeutics Holding Limited. The pact grants VISUfarma the sole right to undertake all regulatory activities, commercialization, marketing, promotion, distribution and sales of YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1%) within the Licensed Territories, which comprise the European Union, the United Kingdom, Switzerland, Norway and Iceland. This arrangement follows Lupin’s strategic acquisition of VISUfarma and is positioned to deepen the company’s footprint in the rapidly growing presbyopia vision‑management segment.
Financial Structure and Milestone Framework
Beyond the licensing rights, VISUfarma will make a strategic investment in Visus Therapeutics. Tenpoint and Visus, either individually or collectively, are entitled to receive regulatory and commercial milestone payments tied to predefined development and sales objectives. In addition, VISUfarma will pay tiered royalties calculated on net sales of YUVEZZI™ in the licensed regions. This blended model aligns the incentives of both parties, ensuring that Lupin gains access to a differentiated ophthalmic asset while Tenpoint retains upside potential tied to the product’s market performance.
Leadership Perspective from Lupin
Vinita Gupta, Chief Executive Officer of Lupin, expressed enthusiasm about the collaboration, stating that the partnership advances Lupin’s Specialty Care strategy by bringing a novel ophthalmic therapy to patients. She highlighted that building on the earlier acquisition of VISUfarma, the deal strengthens Lupin’s vision‑care franchise and expands its presence across major European markets. Gupta underscored that the addition of YUVEZZI™ reflects Lupin’s commitment to broadening access to differentiated therapies, improving patient outcomes, and reinforcing its leadership in eye care throughout the Licensed Territories.
Leadership Perspective from Tenpoint
Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics, described the agreement as an important step toward making YUVEZZI™ available to the millions of patients suffering from presbyopia worldwide. He noted Lupin’s robust commercial operations in major European markets and VISUfarma’s longstanding presence in eyecare as ideal complements to Tenpoint’s mission. Bjarke conveyed optimism about working jointly to launch YUVEZZI™ in Europe and emphasized that the partnership will facilitate broader global reach for the innovative eye‑drop.
Product Overview: YUVEZZI™ Mechanism and Approval
YUVEZZI™ is a once‑daily, dual‑agent ophthalmic solution containing carbachol (2.75%) and brimonidine tartrate (0.1%). It received U.S. FDA approval for the treatment of presbyopia, a condition marked by the gradual loss of near‑vision acuity that typically emerges around age 45. Carbachol acts as a miotic agent, inducing pupil constriction to enhance near focus, while brimonidine counters excessive dilation, thereby stabilizing pupil size throughout the day. This complementary action distinguishes YUVEZZI™ as the first and only approved once‑daily dual‑agent eye drop for presbyopia.
Lupin Corporate Profile
Lupin Limited, headquartered in Mumbai, India, is a global pharmaceutical leader with operations spanning India, the United States, other developed markets and emerging markets, distributing products in over 100 territories. Its diversified portfolio includes generics, complex generics, specialty medicines and biosimilars. Lupin maintains strong leadership in core therapeutic areas such as cardiovascular, respiratory, diabetes, gastrointestinal and women’s health in the U.S. and India. The company operates 15 state‑of‑the‑art manufacturing facilities, six research centers and employs more than 26,000 professionals. Lupin continues to extend its healthcare ecosystem through diagnostics, digital health, patient‑support programs and disease‑management initiatives, with sustainability remaining a core pillar of its business strategy.
Tenpoint Therapeutics Profile
Tenpoint Therapeutics Ltd. is a commercial‑stage ophthalmic pharmaceutical company dedicated to the commercialization of YUVEZZI™, the first and only dual‑agent eye drop for presbyopia. The condition affects roughly 128 million people in the United States and an estimated 2 billion individuals globally. By aligning with eye‑care professionals and focusing on real‑world patient needs, Tenpoint aims to bring innovation to the aging eye. Additional information about the company is available at https://tenpointtherapeutics.com/, and updates can be followed on LinkedIn.
Safety Information and Common Side Effects
The prescribing information for YUVEZZI™ advises against use in patients with known hypersensitivity to any of its components or active iritis. Prior to initiation, clinicians should assess for depression, low blood pressure or circulation problems. The most frequently reported adverse events include headache, impaired vision and temporary eye pain or irritation upon administration; these effects are generally mild, short‑lived and resolve spontaneously. Users may experience transient blurry, dim or dark vision and are cautioned against driving, operating machinery or engaging in hazardous activities if such visual disturbances occur. Immediate medical attention is recommended for sudden flashes of light, floaters or vision loss. Proper handling instructions emphasize avoiding contact between the vial tip and the eye, eyelid or any other surface.
Regulatory Progress and Future Outlook
Tenpoint Therapeutics is actively advancing the commercialization of YUVEZZI™ in the United States following its recent FDA approval. The company has already submitted an MMA (Mutual Recognition Application) in the United Kingdom via the MHRA’s International Recognition Procedure and intends to file regulatory applications in other key regions worldwide. Through the partnership with Lupin’s VISUfarma, Tenpoint anticipates accelerated market entry across Europe, leveraging Lupin’s established commercial infrastructure and ophthalmology expertise. The collaboration is expected to enhance patient access to a novel presbyopia therapy while supporting both companies’ strategic growth objectives.
Strategic Significance of the Partnership
The agreement between VISUfarma and Visus Therapeutics represents a synergistic alignment of Lupin’s expansive global pharmaceutical capabilities and Tenpoint’s focused ophthalmic innovation. By securing exclusive rights to YUVEZZI™ in high‑value European markets, Lupin bolsters its specialty care pipeline and reinforces its commitment to addressing unmet patient needs in vision health. Simultaneously, Tenpoint gains a powerful commercial partner capable of navigating complex European regulatory landscapes and driving rapid adoption of its flagship product. Together, the two entities aim to improve near‑vision outcomes for a growing presbyopic population, setting a new standard in presbyopia management and underscoring the value of cross‑border therapeutic collaborations.